Mealey's (October 6, 2020, 1:53 PM EDT) -- WASHINGTON, D.C. — A challenge by a pharmaceutical company to an August 2019 determination by the Federal Circuit U.S. Court of Appeals that it lacks jurisdiction over allegations that the Patent Trial and Appeal Board violated SAS Institute, Inc. v. Iancu was unsuccessful on Oct. 5, when the U.S. Supreme Court denied certiorari in the case (BioDelivery Sciences International Inc. v. Aquestive Therapeutics Inc., No. 19-1381, U.S. Sup.)....